Chiara Ciccarese

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

N/A

0Author DataRank · unranked

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis”.

Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis

Seminars in Oncology(2019)10.1053/j.seminoncol.2019.01.001

N/A

0.434DataRank · unranked

17 citations

Roberto Iacovelli, Emilio Bria, Claudia Mosillo, Davide Bimbatti, Emanuela Fantinel +4 more

Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide

Expert Review of Anticancer Therapy(2015)10.1586/14737140.2015.1063423

N/A

0.312DataRank · unranked

7 citations

Chiara Ciccarese, Emanuela Fantinel, Davide Bimbatti, Giampaolo Tortora, Francesco Massari +1 more